Neuroprotective Peptides Overview — VialBase Guides

Neuroprotection refers to mechanisms that defend the nervous system against injury, degeneration, and dysfunction. At the cellular level, this involves reducing oxidative stress, suppressing neuroinflammation, supporting neurotrophic factor signaling, and maintaining synaptic integrity. Several peptides have demonstrated relevant activity in this space — ranging from synthetic analogs of endogenous hormones to complex peptide preparations from biological sources.

What Neuroprotection Actually Means

Neuroprotective peptides are not simply “smart drugs.” The term encompasses several distinct biological mechanisms:

Neurotrophic factor upregulation. BDNF (Brain-Derived Neurotrophic Factor), NGF (Nerve Growth Factor), and GDNF (Glial Cell Line-Derived Neurotrophic Factor) support neuron survival, synaptic plasticity, and neurogenesis. Compounds that increase these factors have broad protective effects.

Anti-neuroinflammatory activity. Chronic microglial activation and neuroinflammation are central to Alzheimer’s disease, Parkinson’s disease, and post-traumatic neurological decline. Suppressing IL-1β, TNF-alpha, and NF-κB in the CNS reduces this damage.

Anti-apoptotic signaling. Neurons under stress can undergo programmed cell death. Peptides that inhibit apoptotic pathways (Bcl-2/BAX balance, cytochrome c release) preserve cell populations.

Synaptic maintenance. HGF/Met signaling, synaptogenesis factors, and dendritic spine remodeling all contribute to long-term cognitive capacity.

Semax

Semax (MEHFPGP) is a synthetic heptapeptide analog of the ACTH(4-10) fragment developed in Russia at the Institute of Molecular Genetics. It lacks the hormonal activity of full ACTH but retains and amplifies its central nervous system effects.

Mechanism:

• Rapidly and substantially upregulates BDNF synthesis in the prefrontal cortex and hippocampus
• Increases BDNF receptor (TrkB) expression
• Modulates dopaminergic and serotonergic neurotransmission
• Anti-neuroinflammatory via reduced microglial activation
• Demonstrated neuroprotection in rodent ischemia models

Clinical use: Semax is a registered pharmaceutical in Russia, used clinically for stroke, ischemic brain injury, optic nerve damage, and ADHD-related conditions. Its nootropic reputation in Western research communities comes primarily from its BDNF-raising effects and reported acute enhancement of focus and processing speed.

Delivery: Typically intranasal (nasal spray). The intranasal route provides direct CNS delivery via the olfactory pathway, bypassing the blood-brain barrier challenge that limits many CNS compounds.

Selank

Selank (TKPRPGP) is a synthetic analog of tuftsin (a naturally occurring tetrapeptide from IgG) with an added Pro-Gly-Pro sequence that extends its half-life. It was also developed in Russia, at the Institute of Molecular Genetics.

Mechanism:

• Enhances GABAergic neurotransmission (reducing anxiety without sedation)
• Modulates serotonin and dopamine metabolism — increases their synthesis and reduces breakdown
• Reduces expression of anxiety-related genes
• Modest BDNF upregulation (less pronounced than Semax)
• Modulates IL-6 and other neuroinflammatory cytokines

Character: Selank is distinguished from benzodiazepines and other anxiolytics by the absence of tolerance development, sedation, or dependency in available studies. It is consistently described as producing clear-headed anxiolysis rather than sedation or cognitive blunting.

Clinical use: Registered pharmaceutical in Russia for anxiety disorders and asthenic syndrome (a diagnosis emphasizing fatigue, cognitive inefficiency, and mood dysregulation common in Russian clinical taxonomy).

Delivery: Intranasal, same rationale as Semax.

Dihexa

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small molecule peptide analog derived from angiotensin IV, developed by Joseph Harding’s group at Washington State University. It is structurally distinct from most peptides discussed here and behaves more like a small molecule drug.

Mechanism:

• Potent HGF (Hepatocyte Growth Factor) mimetic — activates the Met receptor with roughly 10^7 (ten million) times greater potency than HGF itself in synaptic plasticity assays
• HGF/Met signaling drives synaptogenesis, dendritic spine formation, and long-term potentiation
• In animal models, Dihexa reversed cognitive deficits induced by aging and TBI with a single administration

Evidence:

• Primarily rodent studies from the Harding group
• No published human trials
• One of the most potent known inducers of synaptogenesis in preclinical models
• HGF promotes cell proliferation in multiple tissues — theoretical oncological concern that has not been resolved in humans

Status: Research compound with no human safety data. Dihexa represents the cutting edge of preclinical neuroprotection research with a compelling mechanistic story, but significant epistemic humility is warranted.

Cortexin

Cortexin is a polypeptide preparation extracted from the cerebral cortex of cattle or pigs, containing a mixture of neuropeptides with molecular weights below 10,000 Da. Developed in Russia, it has pharmaceutical approval there and in several post-Soviet states.

Proposed mechanisms:

• NGF-like neurotrophic activity
• Antioxidant effects in neural tissue
• Reduces excitotoxic damage from glutamate
• Improves cerebral blood flow parameters
• Anti-epileptic effects at higher doses

Clinical use: Used in Russia for cerebrovascular disorders, traumatic brain injury, and in pediatric neurology for developmental delays. The evidence base is similar to other Russian-developed neuropeptide preparations — multiple clinical studies, but methodology varies and independent replication is limited.

Cerebrolysin

Cerebrolysin is a standardized hydrolysate of porcine brain, providing approximately 25% low-molecular-weight peptides and 75% amino acids. Unlike most peptides discussed here, it has been evaluated in multiple multi-center randomized controlled trials.

Proposed mechanisms:

• NGF-like neurotrophic effects
• BDNF upregulation
• Anti-apoptotic (reduces caspase-3 activation)
• Anti-amyloid effects in Alzheimer’s models (reduces APP processing)
• Synaptogenesis support

Evidence:

• Approved in Austria (manufacturer), multiple EU countries, Russia, China, and others for stroke recovery and Alzheimer’s disease
• Multiple RCTs in acute stroke showing improved neurological outcome scores
• Cochrane review noted some trials showing benefit in stroke recovery with acceptable safety; methodology quality was variable
• Alzheimer’s trials show modest positive effects on cognitive endpoints

Route: Intravenous or intramuscular only. Not suitable for subcutaneous administration.

Neuroprotective Peptide Comparison

Stacking Considerations

Semax + Selank: A well-established research combination. Semax addresses BDNF and stimulatory/focus aspects; Selank addresses anxiety, GABAergic balance, and serotonergic regulation. Mechanistically non-overlapping with potential synergy for cognitive clarity without overstimulation.

Semax + BPC-157: BPC-157 has documented CNS effects including modulation of dopaminergic and serotonergic signaling, as well as possible BDNF contributions. Some researchers stack these for traumatic brain injury recovery protocols.

Cerebrolysin + standard neurorehabilitation: In clinical settings, Cerebrolysin is used alongside physical therapy and occupational therapy — the evidence suggests the combination is superior to either alone.

Dihexa caution: Given the absence of human safety data and theoretical oncological concerns around potent HGF agonism, stacking Dihexa with other growth factor-activating compounds is not advisable without a clear understanding of the risk.

Evidence Caveats

The Russian-developed compounds (Semax, Selank, Cortexin) have genuine clinical history and use, but most evidence comes from Russian research groups and the clinical trial literature is not fully accessible in English. This creates an epistemic challenge — the compounds likely work (they are registered pharmaceuticals used in clinical medicine), but the specific effect sizes, optimal dosing, and long-term safety profiles are harder to assess than for Western-approved drugs.

Cerebrolysin has the most internationally replicable evidence base of this group. Dihexa is the most experimental.

This content is for educational purposes only and does not constitute medical advice.